Since HER2 amplification is the second common cause of acquired resistance to Osimertinib in T790M positive lung cancer [27], targeting ANXA1 may help to overcome acquired resistance through the inhibition of HER2 phosphorylation. This evidence concerns the gene ANXA1 and lung carcinoma.